Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | WDR5 | P61964 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2432 | 1.00 | MYC (0.45) | MYCWDR5MMEFFAR1AKR1B1 | |
| SCHEMBL2174 | 1.00 | MYC (0.45) | MYCWDR5MMEFFAR1AKR1B1 | |
| Hydrochloric Acid SCHEMBL15663201 | 0.99 | MYC (0.45) | MYCWDR5MMEFFAR1AKR1B1 | |
| Hydrochloric Acid SCHEMBL3526296 | 0.99 | MYC (0.45) | MYCWDR5MMEFFAR1AKR1B1 | |
| Oxalic Acid SCHEMBL1616541 | 0.97 | MME (0.44) | MYCWDR5MMEFFAR1AKR1B1 | |
| SCHEMBL2465 | 0.90 | MYC (0.43) | MYCWDR5MMEFFAR1AKR1B1 | |
| SCHEMBL3121 | 0.90 | MYC (0.43) | MYCWDR5MMEFFAR1AKR1B1 | |
| SCHEMBL8910310 | 0.89 | ABL1 (0.42) | MYCWDR5MMEFFAR1AKR1B1 | |
| SCHEMBL14004740 | 0.89 | FFAR1 (0.48) | MYCWDR5MMEFFAR1AKR1B1 | |
| SCHEMBL2317 | 0.89 | FFAR1 (0.48) | MYCWDR5MMEFFAR1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140316142-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS AND INTERMEDIATES THEREOF | ALKEM LABORATORIES LTD. (IN) | 2014-10-23 | — | — | US | disclosed |
| US-20140316142-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS AND INTERMEDIATES THEREOF | ALKEM LABORATORIES LTD. (IN) | 2014-10-23 | — | — | US | disclosed |
| WO-2013072924-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS AND INTERMEDIATES THEREOF. | ALKEM LABORATORIES LTD. (IN) | 2013-05-23 | — | — | WO | disclosed |
| WO-2012056294-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-PENTANOYL-N-[[2'-(1H-TETRAZOL-5-YI)[1,1'-BIPHENYL]-4-YI]METHYL]-L-VALINE | JUBILANT LIFE SCIENCES LTD. (IN) | 2012-05-03 | — | — | WO | disclosed |
| US-7880015-B2 | treating N-[[2'-(1-triphenylmethyltetrazol-5-yl)biphenyl-4-yl]methyl]-L-valine methyl ester with oxalic acid to produce N-[[2'-(1-triphenylmethyltetrazol-5-yl)biphenyl-4-yl]methyl]-L-valine methyl ester oxalate, treating intermediate with a base and vlaeryl chloride , deprotecting; Valsartan product | AUROBINDO PHARMA LTD. (IN) | 2011-02-01 | — | — | US | disclosed |
| US-7880015-B2 | treating N-[[2'-(1-triphenylmethyltetrazol-5-yl)biphenyl-4-yl]methyl]-L-valine methyl ester with oxalic acid to produce N-[[2'-(1-triphenylmethyltetrazol-5-yl)biphenyl-4-yl]methyl]-L-valine methyl ester oxalate, treating intermediate with a base and vlaeryl chloride , deprotecting; Valsartan product | AUROBINDO PHARMA LTD. (IN) | 2011-02-01 | — | — | US | disclosed |
| CN-101638393-A | Preparation method of 1-type receptor antagonist of novel hypertension II and application for lowering blood pressure, resisting tumors, and like | ZHILONG CHEN | 2010-02-03 | — | — | CN | disclosed |
| US-20090281326-A1 | Process For the Preparation of Angiotensin II Antagonist | AUROBINDO PHARMA LTD (IN) | 2009-11-12 | — | — | US | disclosed |
| US-20090281326-A1 | Process For the Preparation of Angiotensin II Antagonist | AUROBINDO PHARMA LTD (IN) | 2009-11-12 | — | — | US | disclosed |
| US-7199144-B2 | Process for the preparation of valsartan and intermediates thereof | TEVA PHARMACEUTICALS INDUSTRIES, LTD. (IL) | 2007-04-03 | — | — | US | disclosed |
| US-20050059827-A1 | Process for the preparation of valsartan and intermediates thereof | TEVA PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281326-A1 | Process For the Preparation of Angiotensin II Antagonist | REN, VCL, PTMS | MYC 3156/4885WDR5 1803/4885MME 32/4885 |
| US-20050059827-A1 | Process for the preparation of valsartan and intermediates thereof | REN, AGT, ACE | MYC 4299/4885WDR5 3433/4885MME 18/4885 |
| US-20140316142-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS AND INTERMEDIATES THEREOF | AGTR1, AGTR2, AVPR2 | MYC 3876/4885WDR5 2029/4885MME 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.